

REMARKS

Applicants wish to extend their appreciation to Examiner Robinson for the indication on page 5 of the Official Action that claims 60 and 79 contain allowable subject matter.

Applicants also wish to extend their appreciation to Examiner Robinson for the helpful and courteous discussion held on April 25, 2007, with their undersigned Representative. During the interview, the scope of enablement rejections over claims 60 and 79 were discussed, along with potential amendments and/or arguments for overcoming the rejections. The content of this discussion is believed to be reflected in the remarks set forth herein.

Claims 60-97 are currently pending in the present application. Claims 61-78 and 80-97 were withdrawn from consideration by the Examiner as being drawn to non-elected inventions.

Claims 60 and 79 have been amended to delete recitations of “a solvate thereof” and “an N-oxide thereof.”

Claims 71, 75, 90 and 94 have been amended to delete recitations of “and/or preventing.”

Support for the claim amendments is believed to be provided by the originally filed claims and specification.

It is believed that these claim amendments have not resulted in the introduction of new matter.

The rejection of claims 60 and 79 under 35 U.S.C. § 112, first paragraph (scope of enablement), is obviated by amendment.

As previously discussed, claims 60 and 79 have been amended to delete recitations of “a solvate thereof” and “an N-oxide thereof.”

In view of the foregoing, withdrawal of this ground of rejection is respectfully requested.

Withdrawn claims 61-64 and 80-83 recite a composition comprising at least one compound according to claim 60 and 79, respectively. As such, composition claims 61-64 and 80-83 are commensurate in scope with, and include all of the limitations of, the compounds of claims 60 and 79, respectively.

Withdrawn claims 65-66 and 84-85 recite a process for preparing a composition comprising combining at least one compound according to claim 60 and 79, respectively, with a pharmaceutically acceptable carrier. As such, process claims 65-66 and 84-85 are commensurate in scope with, and include all of the limitations of, the compounds of claims 60 and 79, respectively.

Withdrawn claims 67-70 and 86-89 recite a method of inhibiting activated blood coagulation factor X comprising administering to a mammal in need thereof a therapeutically effective amount of a composition according to claim 61 and 80, respectively, wherein said composition comprises a compound according to claim 60 and 79, respectively. As such, method claims 67-70 and 86-89 are commensurate in scope with, and include all of the limitations of, the compounds of claims 60 and 79, respectively.

Withdrawn claims 71-74 and 90-93 recite a method of treating thrombosis or embolism comprising administering to a mammal in need thereof a therapeutically effective amount of a composition according to claim 61 and 80, respectively, wherein said composition comprises a compound according to claim 60 and 79, respectively. As such, method claims 71-74 and 90-93 are commensurate in scope with, and include all of the limitations of, the compounds of claims 60 and 79, respectively.

Withdrawn claims 75-78 and 94-97 recite a method of treating a condition comprising administering to a mammal in need thereof a therapeutically effective amount of a

Application No. 10/773,344  
Attorney Docket No. 248475US0CIP  
Response to Official Action dated February 26, 2007

composition according to claim 61 and 80, respectively, wherein said composition comprises a compound according to claim 60 and 79, respectively. As such, method claims 75-78 and 94-97 are commensurate in scope with, and include all of the limitations of, the compounds of claims 60 and 79, respectively.

The Examiner is respectfully reminded that in the event that compound claims 60 and 79 of the elected invention are found allowable, composition claims 61-64 and 80-83, process for preparing claims 65-66 and 84-85, method of inhibiting activated blood coagulation factor X claims 67-70 and 86-89, method of treating thrombosis or embolism claims 71-74 and 90-93, and method of treating a condition claims 75-78 and 94-97, which are drawn to non-elected inventions and are commensurate in scope with, and include all of the limitations of, the allowable compound claims, should be rejoined and examined for patentability, pursuant to MPEP § 821.04 and *In re Ochiai*, 71 F.3d 1565, 37 USPQ2d 1127 (Fed. Cir. 1995).

In conclusion, Applicants submit that the present application is now in condition for allowance and notification to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



David P. Stitzel  
Attorney of Record  
Registration No. 44,360

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)